Moss, 3 July 2020
Gentian Diagnostics AS is pleased to announce that the Research Council of Norway (Norges Forskningsråd) has awarded Gentian up to NOK 8.0 million of funding to support the development of a high-throughput COVID-19 antibody test. Gentian has in cooperation with Professor Ørjan Olsvik and Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway performed explorative test work that supports an idea of developing a COVID-19 antibody test based on Gentian’s proprietary technology. The assay, if successfully developed, will be designed for use on clinical analysers already available in major laboratories around the world.
The project will now enter a proof-of-concept phase, and subject to fulfilment of the criteria for this phase the project is intended to undergo a fast track development and planned for launch in 2021.
In the proof-of-concept phase the Company will investigate the technical feasibility, perform a market assessment and if applicable specify the project to develop the assay.
CEO Hilja Ibert commented: “Although at an early stage we are excited to participate towards a solution to manage the COVID-19 pandemic. With Gentian’s technology there is an opportunity to significantly increase testing capacity and make testing available and affordable to all”.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525
MeldingsID: 509241
UtstederID: GENT-ME
Marked: Merkur Market
https://newsweb.oslobors.no/message/509241